A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Key facts
- Study ID
- NCT00567879
- Run by
- Novartis Pharmaceuticals
- People needed
- 56
- Starts
- 2008-04-01
- Expected to finish
- 2011-05-01
- Last updated by the study team
- 2016-05-09
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- University of California at Los Angeles — Los Angeles, California, United States
- University of Colorado Dept. of Univ. of Colorado — Aurora, Colorado, United States
- Norwalk Hospital Dept of Norwalk Hospital (2) — Norwalk, Connecticut, United States
- VA Maryland Health Care Dept.of GreenbaumCancerCent(3) — Baltimore, Maryland, United States
- The Center for Cancer Care and Research — St Louis, Missouri, United States
- Ohio State Comprehensive Cancer Center/James Cancer Hospital SC — Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital — Pittsburgh, Pennsylvania, United States
- Novartis Investigative Site — Kelowna, British Columbia, Canada
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Montreal, Quebec, Canada
- Novartis Investigative Site — Dijon, France
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Saint-Herblain Cédex, France
- Novartis Investigative Site — Heidelberg, Germany
- Novartis Investigative Site — Meldola, FC, Italy
- Novartis Investigative Site — Genova, GE, Italy
- Novartis Investigative Site — Modena, MO, Italy
- Novartis Investigative Site — Birmingham, United Kingdom
- Novartis Investigative Site — London, United Kingdom
- Novartis Investigative Site — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.